Tags

Type your tag names separated by a space and hit enter

Long-term outcomes of HLA-matched sibling compared with mismatched related and unrelated donor hematopoietic stem cell transplantation for chronic phase chronic myelogenous leukemia: a single institution experience in China.
Ann Hematol. 2011 Mar; 90(3):331-41.AH

Abstract

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only curative therapy for chronic myelogenous leukemia (CML). In this study, the long-term outcomes of HLA-matched sibling donor (MSD) with mismatched related donor (MRD) and unrelated donor (URD) transplantation for CML in the first chronic phase (CML-CP1) using different graft vs. host disease (GVHD) prophylaxis regimens according to donor source and the degree of HLA matching were compared. The data of 91 patients with CML-CP1 were analyzed with respect to GVHD, overall survival (OS), and transplant-related mortality (TRM). The incidence of grade II-IV acute GVHD was 25.5% in the MSD and 40.5% in the MRD/URD group (P = 0.133). The 1-year cumulative incidence of chronic GVHD was not different between the MSD and the MRD/URD groups, while extensive chronic GVHD was different between the two groups (31.9% vs. 10.8%, P = 0.023). The 5-year cumulative relapse rate was not different between the MSD and the MRD/URD groups, while TRM was different between the two groups (6.6% vs. 26.3%, P = 0.010). The 5-year cumulative OS was 90.9%, 71.5%, and 85.4% in the MSD, the MRD/URD, and the HLA allele-matched URD transplantation, respectively (MSD vs. MRD/URD, P = 0.013; MSD vs. HLA allele-matched URD, P = 0.437). In conclusion, survival in HLA allele-matched URD is equivalent to MSD, but in MRD and mismatched URD is inferior to MSD in patients with CML-CP1 undergoing allo-HSCT using different GVHD prophylaxis regimens according to donor source and degree of HLA matching. Patients undergoing MRD/URD transplantation have an equal quality of life as patients undergoing MSD transplantation.

Authors+Show Affiliations

Department Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China. liuqifa@fimmu.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Research Support, N.I.H., Extramural

Language

eng

PubMed ID

20872002

Citation

Liu, Qi-fa, et al. "Long-term Outcomes of HLA-matched Sibling Compared With Mismatched Related and Unrelated Donor Hematopoietic Stem Cell Transplantation for Chronic Phase Chronic Myelogenous Leukemia: a Single Institution Experience in China." Annals of Hematology, vol. 90, no. 3, 2011, pp. 331-41.
Liu QF, Xu XJ, Chen YK, et al. Long-term outcomes of HLA-matched sibling compared with mismatched related and unrelated donor hematopoietic stem cell transplantation for chronic phase chronic myelogenous leukemia: a single institution experience in China. Ann Hematol. 2011;90(3):331-41.
Liu, Q. F., Xu, X. J., Chen, Y. K., Sun, J., Zhang, Y., Fan, Z. P., Xu, D., Jiang, Q. L., Wei, Y. Q., Huang, F., Feng, R., Liu, X. L., Xu, B., & Meng, F. Y. (2011). Long-term outcomes of HLA-matched sibling compared with mismatched related and unrelated donor hematopoietic stem cell transplantation for chronic phase chronic myelogenous leukemia: a single institution experience in China. Annals of Hematology, 90(3), 331-41. https://doi.org/10.1007/s00277-010-1081-3
Liu QF, et al. Long-term Outcomes of HLA-matched Sibling Compared With Mismatched Related and Unrelated Donor Hematopoietic Stem Cell Transplantation for Chronic Phase Chronic Myelogenous Leukemia: a Single Institution Experience in China. Ann Hematol. 2011;90(3):331-41. PubMed PMID: 20872002.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Long-term outcomes of HLA-matched sibling compared with mismatched related and unrelated donor hematopoietic stem cell transplantation for chronic phase chronic myelogenous leukemia: a single institution experience in China. AU - Liu,Qi-fa, AU - Xu,Xiao-jun, AU - Chen,Yin-kui, AU - Sun,Jing, AU - Zhang,Yu, AU - Fan,Zhi-ping, AU - Xu,Dan, AU - Jiang,Qian-li, AU - Wei,Yong-qiang, AU - Huang,Fen, AU - Feng,Ru, AU - Liu,Xiao-li, AU - Xu,Bing, AU - Meng,Fan-yi, Y1 - 2010/09/25/ PY - 2010/02/23/received PY - 2010/09/08/accepted PY - 2010/9/28/entrez PY - 2010/9/28/pubmed PY - 2011/3/31/medline SP - 331 EP - 41 JF - Annals of hematology JO - Ann. Hematol. VL - 90 IS - 3 N2 - Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only curative therapy for chronic myelogenous leukemia (CML). In this study, the long-term outcomes of HLA-matched sibling donor (MSD) with mismatched related donor (MRD) and unrelated donor (URD) transplantation for CML in the first chronic phase (CML-CP1) using different graft vs. host disease (GVHD) prophylaxis regimens according to donor source and the degree of HLA matching were compared. The data of 91 patients with CML-CP1 were analyzed with respect to GVHD, overall survival (OS), and transplant-related mortality (TRM). The incidence of grade II-IV acute GVHD was 25.5% in the MSD and 40.5% in the MRD/URD group (P = 0.133). The 1-year cumulative incidence of chronic GVHD was not different between the MSD and the MRD/URD groups, while extensive chronic GVHD was different between the two groups (31.9% vs. 10.8%, P = 0.023). The 5-year cumulative relapse rate was not different between the MSD and the MRD/URD groups, while TRM was different between the two groups (6.6% vs. 26.3%, P = 0.010). The 5-year cumulative OS was 90.9%, 71.5%, and 85.4% in the MSD, the MRD/URD, and the HLA allele-matched URD transplantation, respectively (MSD vs. MRD/URD, P = 0.013; MSD vs. HLA allele-matched URD, P = 0.437). In conclusion, survival in HLA allele-matched URD is equivalent to MSD, but in MRD and mismatched URD is inferior to MSD in patients with CML-CP1 undergoing allo-HSCT using different GVHD prophylaxis regimens according to donor source and degree of HLA matching. Patients undergoing MRD/URD transplantation have an equal quality of life as patients undergoing MSD transplantation. SN - 1432-0584 UR - https://www.unboundmedicine.com/medline/citation/20872002/Long_term_outcomes_of_HLA_matched_sibling_compared_with_mismatched_related_and_unrelated_donor_hematopoietic_stem_cell_transplantation_for_chronic_phase_chronic_myelogenous_leukemia:_a_single_institution_experience_in_China_ L2 - https://dx.doi.org/10.1007/s00277-010-1081-3 DB - PRIME DP - Unbound Medicine ER -